Glatiramer Acetate in the Treatment of Multiple Sclerosis

B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity

(2010) Martin S. Weber et al.   ANNALS OF NEUROLOGY

Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis

(2010) Sakhina Begum-Haque et al.   JOURNAL OF NEUROIMMUNOLOGY

Long-term treatment of multiple sclerosis with glatiramer acetate: Natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy

(2010) Dimitros Karussis et al.   JOURNAL OF NEUROIMMUNOLOGY

Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes

(2010) Rakel Carpintero et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis

(2009) Mrinalini Kala et al.   EXPERIMENTAL NEUROLOGY

Long-Term Study of Brain1H-MRS Study in Multiple Sclerosis: Effect of Glatiramer Acetate Therapy on Axonal Metabolic Function and Feasibility of Long-Term1H-MRS Monitoring in Multiple Sclerosis

(2009) Omar Khan et al.   JOURNAL OF NEUROIMAGING

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate

(2009) V. Skihar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1  in human monocytes and multiple sclerosis

(2009) D. Burger et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Exacerbation of autoimmune arthritis by copolymer-I through promoting type 1 immune response and autoantibody production

(2008) Biao Zheng et al.   AUTOIMMUNITY

Regulatory B cells as inhibitors of immune responses and inflammation

(2008) Jean-David Bouaziz et al.   IMMUNOLOGICAL REVIEWS

Glatiramer acetate: A novel therapeutic approach in Crohnʼs disease?

(2008) Albrecht Neesse et al.   INFLAMMATORY BOWEL DISEASES

Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model

(2008) P. Borel et al.   INTERNATIONAL IMMUNOLOGY

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis

(2008) R. Aharoni et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells

(2008) T. Korn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA